In Poland, since 1 April 2025, CFTR modulators Kaftrio + Kalydeco (ivacaftor + tezacaftor + elexacaftor and ivacaftor) have been used as drugs for cystic fibrosis patients from 2 years of age. The gene discussed is CFTR; the disease is cystic fibrosis.